Clovis Oncology (CLVS) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Clovis Oncology (CLVS) Pushes to Highs Following Results; Still Seen as Valuable Takeover Target
February 27, 2019 1:27 PM ESTClovis Oncology (NASDAQ: CLVS) pushes to highs following results. Shares are up 18%. Analysts continue to see the company as an attractive takeover target.
Gabelli's Jing He commented, "We believe Rubraca is a valuable asset with potential in additional tumor types. However, with... More
Clovis Oncology (CLVS) PT Raised to $33 at RBC Capital
February 27, 2019 6:48 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining a Outperform rating.
While no 2019 guidance, they like the setup for beats versus the Street for the year ahead.
... MoreClovis Oncology (CLVS) PT Raised to $23 at Piper Jaffray
February 27, 2019 3:00 AM ESTPiper Jaffray analyst Joseph Catanzaro raised the price target on Clovis Oncology (NASDAQ: CLVS) to $23.00 (from $18.00) while maintaining a Neutral rating.
... More